ProKidney Corp
PROK2.710USD
+0.180+7.11%
終値 09/18, 16:00（ET）15分遅れの株価
361.57M時価総額
損失額直近12ヶ月PER
詳細情報 ProKidney Corp 企業名
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
企業情報
企業コードPROK
会社名ProKidney Corp
上場日Jun 30, 2021
最高経営責任者「CEO」Dr. Bruce Culleton, M.D.
従業員数204
証券種類Ordinary Share
決算期末Jun 30
本社所在地2000 Frontis Plaza Blvd.
都市WINSTON-SALEM
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号27103
電話番号13369997028
ウェブサイトhttps://prokidney.com/
企業コードPROK
上場日Jun 30, 2021
最高経営責任者「CEO」Dr. Bruce Culleton, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Lucio Tozzi
Mr. Lucio Tozzi
Senior Vice President - Global Clinical Operations
Senior Vice President - Global Clinical Operations
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
株主統計
種類
株主統計
株主統計
比率
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
他の
59.39%
株主統計
株主統計
比率
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
他の
59.39%
種類
株主統計
比率
Corporation
24.70%
Investment Advisor
10.51%
Hedge Fund
10.27%
Investment Advisor/Hedge Fund
5.98%
Research Firm
2.88%
Individual Investor
1.92%
Endowment Fund
0.74%
Family Office
0.04%
Bank and Trust
0.04%
他の
42.93%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
2023Q1
183
53.54M
87.01%
-23.74M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Tolerantia LLC
22.62M
17.46%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.53%
--
--
Mar 31, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
8.28%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
10.04M
7.75%
-3.51M
-25.90%
Mar 31, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.65%
--
--
Mar 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.89%
--
--
May 31, 2025
Bleichroeder LP
2.00M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
4.88%
+8.24K
+0.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.21M
4.02%
-63.88K
-1.21%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
